CytomX Therapeutics, Inc. (CTMX) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Revenue CTMX has positive revenue for last 5 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth CTMX has never had growing revenue.
Net Income Growth CTMX has never had growing net income.
Price to Book (PBV) Ratio Overvalued price-to-book. CTMX stock price is overvalued by more than 2x the price-to-book value.
Net Income CTMX never has positive net income for 2 years.
Debt-Equity Ratio (DER) CTMX debt is 6.95x it's equity.
Dividend Yield CTMX has low dividend yield (0%).
Return of Assets CTMX has low return of asset (-43.09%).
Return of Equity CTMX has low return of equity (-166.29%).
Return of Invested Capital CTMX has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-120,640,000 USD

Dividend

Financial Ratios

CEO

CEO Name

DR. Sean McCarthy

Management

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Additional Information

Company name

CytomX Therapeutics, Inc.

Symbol

NASDAQ:CTMX

Exchange

NASDAQ Global Select

Industry

Biotechnology

Sector

Healthcare

Address

151 Oyster Point Blvd Ste 400
South San Francisco
CALIFORNIA
US
94080

Website

https://www.cytomx.com